Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

GlobalData, December 2012, Pages: 264

Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

Summary

Our new report, “Austria In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Austria In Vitro Diagnostics market. The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within market categories – Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Immuno Chemistry, Infectious Immunology, Clinical Chemistry, Haematology, Microbiology Culture, Histology And Cytology and Genetic Testing.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2011 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the Austria In Vitro Diagnostics market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Beckman Coulter, Inc., bioMerieux S.A., Ortho-Clinical Diagnostics Inc. and others.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Austria In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What is This Report About?
3 In Vitro Diagnostics In Austria
3.1 In Vitro Diagnostics, Market Segmentation
3.2 In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018
3.3 In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011
3.4 In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011
3.5 In Vitro Diagnostics, Austria, Company Share (2010-2011)
4 Clinical Chemistry In Austria
4.1 Clinical Chemistry, Market Segmentation
4.2 Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011
4.3 Clinical Chemistry Market, Austria, Segment Contribution (%), 2011
4.4 Clinical Chemistry Overall Revenue, (2004-2018)
4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018)
4.4.2 Urine Analysis, Revenue (2004-2018)
4.5 Clinical Chemistry Distribution Share (2010-2011)
4.6 Clinical Chemistry, Austria, Company Share (2010-2011)
5 Genetic Testing In Austria
5.1 Genetic Testing, Market Segmentation
5.2 Genetic Testing Market, Austria, Revenue Mix ($m), 2011
5.3 Genetic Testing Market, Austria, Segment Contribution (%), 2011
5.4 Genetic Testing Overall Revenue, (2004-2018)
5.5 Genetic Testing Distribution Share (2010-2011)
5.6 Genetic Testing, Austria, Company Share (2010-2011)
6 Haematology In Austria
6.1 Haematology Market, Market Segmentation
6.2 Haematology Market, Austria, Revenue Mix ($m), 2011
6.3 Haematology Market, Austria, Segment Contribution (%), 2011
6.4 Haematology Overall Revenue, (2004-2018)
6.4.1 Haematology Reagents, Revenue (2004-2018)
6.4.2 Immunohaematology, Revenue (2004-2018)
6.4.3 Haemostasis, Revenue (2004-2018)
6.4.4 Haematology Rapid Tests, Revenue (2004-2018)
6.4.5 Haematology Cell Counters, Revenue (2004-2018)
6.5 Haematology Distribution Share (2010-2011)
6.6 Haematology, Austria, Company Share (2010-2011)
7 Histology And Cytology In Austria
7.1 Histology and Cytology Market, Market Segmentation
7.2 Histology And Cytology Market, Austria, Revenue Mix ($m), 2011
7.3 Histology And Cytology Market, Austria, Segment Contribution (%), 2011
7.4 Histology And Cytology Overall Revenue, (2004-2018)
7.5 Histology And Cytology Distribution Share (2010-2011)
7.6 Histology And Cytology, Austria, Company Share (2010-2011)
8 Immuno Chemistry In Austria
8.1 Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011
8.2 Immuno Chemistry Market, Austria, Segment Contribution (%), 2011
8.3 Immuno Chemistry Overall Revenue, (2004-2018)
8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018)
8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018)
8.3.3 Endocrinology Tests, Revenue (2004-2018)
8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018)
8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018)
8.3.6 Immunochemistry Analyzers, Revenue (2004-2018)
8.4 Immuno Chemistry Distribution Share (2010-2011)
8.5 Immuno Chemistry, Austria, Company Share (2010-2011)
9 Infectious Immunology In Austria
9.1 Infectious Immunology, Market Segmentation
9.2 Infectious Immunology Market, Austria, Revenue Mix ($m), 2011
9.3 Infectious Immunology Market, Austria, Segment Contribution (%), 2011
9.4 Infectious Immunology Overall Revenue, (2004-2018)
9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018)
9.5 Infectious Immunology Distribution Share (2010-2011)
9.6 Infectious Immunology, Austria, Company Share (2010-2011)
10 Microbiology Culture In Austria
10.1 Microbiology Culture, Market Segmentation
10.2 Microbiology Culture Market, Austria, Revenue Mix ($m), 2011
10.3 Microbiology Culture Market, Austria, Segment Contribution (%), 2011
10.4 Microbiology Culture Overall Revenue, (2004-2018)
10.4.1 Microbiology Analyzers, Revenue (2004-2018)
10.5 Microbiology Culture Distribution Share (2010-2011)
10.6 Microbiology Culture, Austria, Company Share (2010-2011)
11 Overview of Key Companies in Austria In Vitro Diagnostics Market
11.1 F. Hoffmann-La Roche Ltd.
11.1.1 Company Overview
11.1.2 Share in the Austria In Vitro Diagnostics Market
11.2 Siemens Healthcare
11.2.1 Company Overview
11.2.2 Share in the Austria In Vitro Diagnostics Market
11.3 Abbott Laboratories
11.3.1 Company Overview
11.3.2 Share in the Austria In Vitro Diagnostics Market
11.4 Beckman Coulter, Inc.
11.4.1 Company Overview
11.4.2 Share in the Austria In Vitro Diagnostics Market
11.5 bioMerieux S.A.
11.5.1 Company Overview
11.5.2 Share in the Austria In Vitro Diagnostics Market
11.6 Ortho-Clinical Diagnostics Inc.
11.6.1 Company Overview
11.6.2 Share in the Austria In Vitro Diagnostics Market
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Company Overview
11.8 Sysmex Corporation
11.8.1 Company Overview
11.9 Alere Inc.
11.9.1 Company Overview
11.10 Becton, Dickinson and Company
11.10.1 Company Overview
11.11 Qiagen N.V.
11.11.1 Company Overview
11.12 DiaSorin S.p.A
11.12.1 Company Overview
11.13 Gen-Probe Incorporated
11.13.1 Company Overview
11.14 Danaher Corporation
11.14.1 Company Overview
11.15 Diagnostica Stago, Inc.
11.15.1 Company Overview
11.16 PerkinElmer, Inc.
11.16.1 Company Overview
11.17 Thermo Fisher Scientific Inc.
11.17.1 Company Overview
11.18 Horiba, Ltd.
11.18.1 Company Overview
11.19 Grifols, S.A.
11.19.1 Company Overview
11.20 Immucor, Inc.
11.20.1 Company Overview
11.21 Phadia AB
11.21.1 Company Overview
11.22 Life Technologies Corporation
11.22.1 Company Overview
12 In Vitro Diagnostics Market Pipeline Products
12.1 Clinical Chemisty Market Pipeline Products
12.2 Immuno Chemistry Market Pipeline Products
12.3 Haematology Market Pipeline Products
12.4 Infectious Immunology Market Pipeline Products
12.5 Microbiology Culture Market Pipeline Products
12.6 Histology And Cytology Market Pipeline Products
12.7 Genetic Testing Market Pipeline Products
13 Financial Deals Landscape
13.1 Partnerships
13.1.1 Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay
13.1.2 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology
13.1.3 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System
13.1.4 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
13.1.5 BioDot Enters Into Co-Marketing Agreement With JOT Automation
13.1.6 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays
13.1.7 CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions
13.1.8 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test
13.1.9 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
13.1.10 Life Technologies Enters Into Co-Marketing Agreement With Pathogenica
13.1.11 CML HealthCare Enters Into Agreement With MaRS Innovation
13.1.12 Akrivis Technologies Enters Into Co-Development Agreement With United States Biological
13.1.13 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test
13.1.14 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products
13.1.15 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina
13.1.16 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test
13.1.17 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor
13.1.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
13.1.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
13.1.20 Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays
13.1.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
13.1.22 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis
13.1.23 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test
13.1.24 One Lambda Enters Into Co-Marketing Agreement With CellTrend
13.1.25 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker
13.1.26 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems
13.1.27 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
13.1.28 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology
13.1.29 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA
13.1.30 Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products
13.1.31 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit
13.1.32 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo
13.1.33 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology
13.1.34 LipoScience Enters Into Licensing Agreement With Cleveland Clinic
13.1.35 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System
13.1.36 NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers
13.1.37 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX
13.1.38 Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis
13.1.39 Roche Enters Into Co-Development Agreement With Technoclone
13.1.40 Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences
13.1.41 Sony DADC Enters Into Co-Development Agreement With Axela
13.1.42 Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies
14 Recent Developments
14.1 Product News
14.1.1 Sep 28, 2012: Anagnostics Announces Availability Of hybcell Pathogens DNA plexA As CE-IVD Test
14.1.2 Sep 27, 2011: Data From Evaluation Of Asuragen’s Signature LTx Leukemia Test To Be Presented At Upcoming Planet XMAP In Vienna, Austria
15 Appendix
15.1 Definitions of Markets Covered in the Report
15.1.1 In Vitro Diagnostics
15.2 Research Methodology
15.3 Secondary Research
15.4 Primary Research
15.5 Models
15.6 Forecasts
15.7 Expert Panels
15.8 Consulting
15.9 Currency Conversion
15.10 Contact Us
15.11 Disclaimer

1.1 List of Tables
Table 1: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018
Table 2: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011
Table 3: In Vitro Diagnostics Market, Austria, Cross-Category Analysis, 2004-2018
Table 4: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Table 5: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Table 6: In Vitro Diagnostics, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 7: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011
Table 8: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 9: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 10: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 11: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 12: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 13: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 14: Clinical Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 15: Clinical Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 16: Genetic Testing Market, Austria, Segment Contribution (%), 2011
Table 17: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 18: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 19: Genetic Testing, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 20: Genetic Testing, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 21: Haematology Market, Austria, Segment Contribution (%), 2011
Table 22: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 23: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 24: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 25: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 26: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 27: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 28: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 29: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 30: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 31: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 32: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 33: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 34: Haematology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 35: Haematology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 36: Histology And Cytology Market, Austria, Segment Contribution (%), 2011
Table 37: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 38: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 39: Histology And Cytology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 40: Histology And Cytology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 41: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011
Table 42: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 43: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 44: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 45: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 46: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 47: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 48: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 49: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 50: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 51: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 52: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 53: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 54: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 55: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 56: Immuno Chemistry, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 57: Immuno Chemistry, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 58: Infectious Immunology Market, Austria, Segment Contribution (%), 2011
Table 59: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 60: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 61: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 62: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 63: Infectious Immunology, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 64: Infectious Immunology, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 65: Microbiology Culture Market, Austria, Segment Contribution (%), 2011
Table 66: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Table 67: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Table 68: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Table 69: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Table 70: Microbiology Culture, Austria, Distribution Share by Revenue ($m), USD Constant, 2010-2011
Table 71: Microbiology Culture, Austria, Company Share by Revenue ($m), USD Constant, 2010-2011
Table 72: Clinical Chemisty Market Pipeline Products
Table 73: Immuno Chemistry Market Pipeline Products
Table 74: Haematology Market Pipeline Products
Table 75: Infectious Immunology Market Pipeline Products
Table 76: Microbiology Culture Market Pipeline Products
Table 77: Histology And Cytology Market Pipeline Products
Table 78: Genetic Testing Market Pipeline Products
Table 79: Cisbio Bioassays Enters Into Distribution Agreement With BellBrook Labs For Transcreener Epigen Methyltransferase Assay
Table 80: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology
Table 81: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System
Table 82: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ
Table 83: BioDot Enters Into Co-Marketing Agreement With JOT Automation
Table 84: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays
Table 85: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital Microscopy Hematology Solutions
Table 86: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test
Table 87: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology
Table 88: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica
Table 89: CML HealthCare Enters Into Agreement With MaRS Innovation
Table 90: Akrivis Technologies Enters Into Co-Development Agreement With United States Biological
Table 91: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women's Hospital For Mesothelioma Test
Table 92: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products
Table 93: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina
Table 94: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test
Table 95: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor
Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International
Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test
Table 98: Kreatech Diagnostics Enters Into Co-Development Agreement With Oridis Biomarkers For DNA-FISH Assays
Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus
Table 100: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis
Table 101: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test
Table 102: One Lambda Enters Into Co-Marketing Agreement With CellTrend
Table 103: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker
Table 104: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems
Table 105: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker
Table 106: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology
Table 107: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA
Table 108: Nanosphere Enters Into Co-Marketing Agreement With Thermo Fisher For Verigene Products
Table 109: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit
Table 110: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo
Table 111: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology
Table 112: LipoScience Enters Into Licensing Agreement With Cleveland Clinic
Table 113: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System
Table 114: NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers
Table 115: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX
Table 116: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis
Table 117: Roche Enters Into Co-Development Agreement With Technoclone
Table 118: Amorfix Life Sciences Enters Into Licensing Agreement With JSW-Lifesciences
Table 119: Sony DADC Enters Into Co-Development Agreement With Axela
Table 120: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies

1.2 List of Figures
Figure 1: In Vitro Diagnostics, Market Segmentation
Figure 2: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, 2004-2018
Figure 3: In Vitro Diagnostics Market, Austria, Revenue Mix ($m), 2011
Figure 4: In Vitro Diagnostics Market, Austria, Category Contribution (%), 2011
Figure 5: In Vitro Diagnostics Market Austria, Cross-Category Analysis, 2004-2018
Figure 6: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Historic, 2004-2011
Figure 7: In Vitro Diagnostics, Austria, Overall Revenue ($m), USD Constant, Forecast, 2011-2018
Figure 8: In Vitro Diagnostics, Austria, Company Share (%), 2011
Figure 9: Clinical Chemistry, Market Segmentation
Figure 10: Clinical Chemistry Market, Austria, Revenue Mix ($m), 2011
Figure 11: Clinical Chemistry Market, Austria, Segment Contribution (%), 2011
Figure 12: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 13: Clinical Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 14: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 15: Clinical Chemisty Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 16: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 17: Urine Analysis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 18: Clinical Chemistry, Austria, Company Share (%), 2011
Figure 19: Genetic Testing, Market Segmentation
Figure 20: Genetic Testing Market, Austria, Revenue Mix ($m), 2011
Figure 21: Genetic Testing Market, Austria, Segment Contribution (%), 2011
Figure 22: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 23: Genetic Testing, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 24: Genetic Testing, Austria, Company Share (%), 2011
Figure 25: Haematology Market, Market Segmentation
Figure 26: Haematology Market, Austria, Revenue Mix ($m), 2011
Figure 27: Haematology Market, Austria, Segment Contribution (%), 2011
Figure 28: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 29: Haematology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 30: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 31: Haematology Reagents, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 32: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 33: Immunohaematology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 34: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 35: Haemostasis, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 36: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 37: Haematology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 38: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 39: Haematology Cell Counters, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 40: Haematology, Austria, Company Share (%), 2011
Figure 41: Histology and Cytology Market, Market Segmentation
Figure 42: Histology And Cytology Market, Austria, Revenue Mix ($m), 2011
Figure 43: Histology And Cytology Market, Austria, Segment Contribution (%), 2011
Figure 44: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 45: Histology And Cytology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 46: Histology And Cytology, Austria, Company Share (%), 2011
Figure 47: Immuno Chemistry Market, Austria, Revenue Mix ($m), 2011
Figure 48: Immuno Chemistry Market, Austria, Segment Contribution (%), 2011
Figure 49: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 50: Immuno Chemistry, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 51: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 52: Disease Specific Immunochemistry, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 53: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 54: Drugs of Abuse / Toxicology, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 55: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 56: Endocrinology Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 57: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 58: Immunochemistry Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 59: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 60: Therapeutic Drug Monitoring, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 61: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 62: Immunochemistry Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 63: Immuno Chemistry, Austria, Company Share (%), 2011
Figure 64: Infectious Immunology, Market Segmentation
Figure 65: Infectious Immunology Market, Austria, Revenue Mix ($m), 2011
Figure 66: Infectious Immunology Market, Austria, Segment Contribution (%), 2011
Figure 67: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 68: Infectious Immunology, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 69: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 70: Infectious Immunology Rapid Tests, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 20011-2018
Figure 71: Infectious Immunology, Austria, Company Share (%), 2011
Figure 72: Microbiology Culture, Market Segmentation
Figure 73: Microbiology Culture Market, Austria, Revenue Mix ($m), 2011
Figure 74: Microbiology Culture Market, Austria, Segment Contribution (%), 2011
Figure 75: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011
Figure 76: Microbiology Culture, Austria, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018
Figure 77: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011
Figure 78: Microbiology Analyzers, Austria, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018
Figure 79: Microbiology Culture, Austria, Company Share (%), 2011
Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Austria In Vitro Diagnostics Market, 2011
Figure 81: Siemens Healthcare, Company Share (%),Austria In Vitro Diagnostics Market, 2011
Figure 82: Abbott Laboratories, Company Share (%),Austria In Vitro Diagnostics Market, 2011
Figure 83: Beckman Coulter, Inc., Company Share (%),Austria In Vitro Diagnostics Market, 2011
Figure 84: bioMerieux S.A., Company Share (%),Austria In Vitro Diagnostics Market, 2011
Figure 85: Ortho-Clinical Diagnostics Inc., Company Share (%),Austria In Vitro Diagnostics Market, 2011

F. Hoffmann-La Roche Ltd.
Siemens Healthcare
Abbott Laboratories
Beckman Coulter, Inc.
bioMerieux S.A.
Ortho-Clinical Diagnostics Inc.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Alere Inc.
Becton, Dickinson and Company
Qiagen N.V.
DiaSorin S.p.A
Gen-Probe Incorporated
Danaher Corporation
Diagnostica Stago, Inc.
PerkinElmer, Inc.
Thermo Fisher Scientific Inc.
Horiba, Ltd.
Grifols, S.A.
Immucor, Inc.
Phadia AB
Life Technologies Corporation

Customers who bought this item also bought

• Austria In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Canada In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Denmark In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Belgium In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Italy In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• France In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Sweden In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Czech Republic In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Germany In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
• Israel In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture